Search hospitals > Ohio > Columbus

Nationwide Children's Hospital

Claim this profile
Columbus, Ohio 43205
Global Leader in Brain Tumor
Global Leader in Cancer
Conducts research for Cystic Fibrosis
Conducts research for Leukemia
Conducts research for Acute Lymphoblastic Leukemia
1069 reported clinical trials
67 medical researchers
Photo of Nationwide Children's Hospital in ColumbusPhoto of Nationwide Children's Hospital in ColumbusPhoto of Nationwide Children's Hospital in Columbus

Summary

Nationwide Children's Hospital is a medical facility located in Columbus, Ohio. This center is recognized for care of Brain Tumor, Cancer, Cystic Fibrosis, Leukemia, Acute Lymphoblastic Leukemia and other specialties. Nationwide Children's Hospital is involved with conducting 1,069 clinical trials across 1,318 conditions. There are 67 research doctors associated with this hospital, such as Mark Ranalli, Pablo Sanchez, MD, Maryam Fouladi, MD, and Bhuvana Setty, M.D..

Area of expertise

1Brain Tumor
Global Leader
Nationwide Children's Hospital has run 93 trials for Brain Tumor. Some of their research focus areas include:
Stage IV
NTRK positive
Stage I
2Cancer
Global Leader
Nationwide Children's Hospital has run 81 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage I
Stage II

Top PIs

Clinical Trials running at Nationwide Children's Hospital

Neuroblastoma
Brain Tumor
Testicular cancer
Cystic Fibrosis
Cardiovascular Disease
Cancer
Crohn's Disease
Ovarian Carcinoma
Ovarian Tumors
Testicular Carcinoma
Image of trial facility.

Dinutuximab + Chemotherapy

for High-Risk Neuroblastoma

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting2 awards Phase 37 criteria
Image of trial facility.

Lorlatinib + Standard Therapy

for Neuroblastoma

This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Recruiting2 awards Phase 322 criteria
Image of trial facility.

Biology Study

for Neuroblastoma

Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.
Recruiting1 award N/A4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Nationwide Children's Hospital?
Where is Nationwide Children's Hospital located?
Who should I call to ask about financial aid or insurance network?
What insurance does Nationwide Children's Hospital accept?
What awards or recognition has Nationwide Children's Hospital received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security